See more : Fat Projects Acquisition Corp (FATPW) Income Statement Analysis – Financial Results
Complete financial analysis of Thermo Fisher Scientific Inc. (TMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Thermo Fisher Scientific Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Solution Dynamics Limited (SDL.NZ) Income Statement Analysis – Financial Results
- Made.com Group Plc (MADE.L) Income Statement Analysis – Financial Results
- Varta AG (VARGF) Income Statement Analysis – Financial Results
- PT Wilton Makmur indonesia Tbk. (SQMI.JK) Income Statement Analysis – Financial Results
- Weyerhaeuser Company (0LWG.L) Income Statement Analysis – Financial Results
Thermo Fisher Scientific Inc. (TMO)
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.86B | 44.92B | 39.21B | 32.22B | 25.54B | 24.36B | 20.92B | 18.27B | 16.97B | 16.89B | 13.09B | 12.51B | 11.73B | 10.79B | 10.11B | 10.50B | 9.75B | 3.79B | 2.63B | 2.21B | 2.10B | 2.09B | 2.19B | 2.28B | 2.47B | 3.87B | 3.56B | 2.93B | 2.21B | 1.59B | 1.25B | 949.00M | 805.50M | 708.00M | 579.00M | 500.60M | 383.40M | 331.60M | 265.70M |
| Cost of Revenue | 25.74B | 25.42B | 18.98B | 15.71B | 13.72B | 12.99B | 10.96B | 9.46B | 8.78B | 8.97B | 7.34B | 6.99B | 6.74B | 6.22B | 5.96B | 6.29B | 5.94B | 2.22B | 1.44B | 1.19B | 1.15B | 1.16B | 1.23B | 1.26B | 1.26B | 2.02B | 1.84B | 1.54B | 1.12B | 866.30M | 713.10M | 579.80M | 510.20M | 443.00M | 384.10M | 325.70M | 248.70M | 219.30M | 174.30M |
| Gross Profit | 17.11B | 19.50B | 20.23B | 16.51B | 11.83B | 11.36B | 9.96B | 8.82B | 8.18B | 7.92B | 5.75B | 5.52B | 4.99B | 4.57B | 4.15B | 4.21B | 3.80B | 1.57B | 1.19B | 1.01B | 948.02M | 927.38M | 958.62M | 1.02B | 1.21B | 1.84B | 1.72B | 1.39B | 1.08B | 719.00M | 536.60M | 369.20M | 295.30M | 265.00M | 194.90M | 174.90M | 134.70M | 112.30M | 91.40M |
| Gross Profit Ratio | 39.93% | 43.42% | 51.60% | 51.23% | 46.30% | 46.65% | 47.60% | 48.24% | 48.23% | 46.89% | 43.93% | 44.10% | 42.54% | 42.39% | 41.04% | 40.07% | 39.03% | 41.36% | 45.38% | 45.99% | 45.21% | 44.45% | 43.81% | 44.81% | 48.81% | 47.65% | 48.36% | 47.40% | 49.05% | 45.35% | 42.94% | 38.90% | 36.66% | 37.43% | 33.66% | 34.94% | 35.13% | 33.87% | 34.40% |
| Research & Development | 1.34B | 1.47B | 1.41B | 1.18B | 1.00B | 967.00M | 888.00M | 754.80M | 692.30M | 691.10M | 395.50M | 376.40M | 340.60M | 287.20M | 246.10M | 249.10M | 238.70M | 170.18M | 152.78M | 134.68M | 146.39M | 155.12M | 171.61M | 176.76M | 171.10M | 367.30M | 337.30M | 0.00 | 269.60M | 103.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.45B | 7.13B | 6.84B | 5.76B | 4.93B | 4.82B | 4.41B | 4.04B | 3.72B | 3.99B | 2.91B | 2.83B | 2.65B | 2.39B | 2.20B | 2.69B | 2.55B | 1.11B | 761.79M | 626.46M | 568.14M | 564.66M | 620.10M | 646.92M | 673.00M | 937.60M | 840.70M | 990.70M | 480.80M | 373.20M | 370.60M | 271.70M | 233.60M | 210.60M | 164.40M | 144.60M | 117.10M | 91.60M | 78.70M |
| Other Expenses | 536.00M | 2.40B | 1.76B | 1.67B | 1.71B | 9.00M | -28.00M | -4.10M | -15.50M | 16.40M | -56.00M | 3.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 113.60M | 162.30M | 135.70M | 115.20M | 85.00M | 62.30M | 42.40M | 29.20M | 23.40M | 18.80M | 12.70M | 11.10M | 10.10M | 8.40M | 7.80M |
| Operating Expenses | 10.24B | 10.99B | 10.01B | 8.61B | 7.65B | 7.53B | 6.89B | 6.18B | 5.73B | 6.01B | 4.06B | 3.95B | 3.64B | 3.25B | 3.04B | 2.94B | 2.79B | 1.28B | 914.56M | 761.14M | 714.53M | 719.78M | 791.72M | 823.68M | 957.70M | 1.47B | 1.31B | 1.11B | 835.40M | 539.20M | 413.00M | 300.90M | 257.00M | 229.40M | 177.10M | 155.70M | 127.20M | 100.00M | 86.50M |
| Cost & Expenses | 36.00B | 36.41B | 28.99B | 24.33B | 21.36B | 20.53B | 17.85B | 15.64B | 14.51B | 14.98B | 11.40B | 10.95B | 10.38B | 9.46B | 9.00B | 9.23B | 8.73B | 3.50B | 2.35B | 1.95B | 1.86B | 1.88B | 2.02B | 2.08B | 2.22B | 3.49B | 3.15B | 2.65B | 1.96B | 1.41B | 1.13B | 880.70M | 767.20M | 672.40M | 561.20M | 481.40M | 375.90M | 319.30M | 260.80M |
| Interest Income | 879.00M | 272.00M | 43.00M | 65.00M | 224.00M | 137.00M | 81.00M | 48.40M | 30.60M | 47.70M | 28.00M | 25.20M | 26.90M | 12.50M | 16.10M | 51.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.38B | 726.00M | 536.00M | 553.00M | 676.00M | 667.00M | 592.00M | 469.60M | 414.90M | 479.90M | 262.10M | 241.60M | 175.30M | 84.70M | 118.10M | 151.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.41B | 3.38B | 2.59B | 2.33B | 2.28B | 2.27B | 2.03B | 1.76B | 1.69B | 1.68B | 999.90M | 983.70M | 863.50M | 770.00M | 787.30M | 792.70M | 756.80M | 240.77M | 123.27M | 66.14M | 58.55M | 56.38M | 98.52M | 97.49M | 113.60M | 162.30M | 135.70M | 115.20M | 85.00M | 62.30M | 42.40M | 29.20M | 23.40M | 18.80M | 12.70M | 11.10M | 10.10M | 8.40M | 7.80M |
| EBITDA | 11.20B | 11.94B | 12.96B | 10.19B | 6.46B | 6.20B | 5.25B | 4.25B | 4.04B | 4.25B | 2.58B | 2.49B | 2.18B | 1.91B | 1.83B | 2.07B | 1.78B | 502.07M | 435.89M | 336.34M | 279.30M | 193.08M | 265.43M | 295.65M | 362.20M | 353.40M | 371.60M | 399.40M | 332.30M | 242.10M | 166.00M | 97.50M | 61.70M | 54.40M | 30.50M | 30.30M | 17.60M | 20.70M | 12.70M |
| EBITDA Ratio | 26.12% | 26.84% | 31.03% | 31.67% | 25.88% | 25.64% | 24.62% | 24.30% | 24.49% | 21.63% | 20.31% | 20.60% | 19.07% | 19.54% | 18.92% | 19.95% | 18.65% | 15.11% | 14.55% | 14.22% | 14.63% | 9.25% | 16.53% | 13.55% | 23.20% | 13.51% | 12.97% | 10.53% | 9.21% | 10.02% | 12.68% | 4.16% | 0.30% | 2.53% | -0.14% | 1.96% | -1.85% | 3.44% | 0.45% |
| Operating Income | 6.86B | 8.39B | 10.03B | 7.79B | 4.59B | 3.78B | 2.97B | 2.45B | 2.34B | 2.50B | 1.61B | 1.48B | 1.25B | 1.26B | 1.05B | 1.23B | 974.40M | 241.96M | 263.49M | 237.51M | 184.77M | 155.45M | 34.20M | 198.16M | 248.60M | 375.80M | 407.00M | 284.20M | 247.30M | 179.80M | 123.60M | 68.30M | 38.30M | 35.60M | 17.80M | 19.20M | 7.50M | 12.30M | 4.90M |
| Operating Income Ratio | 16.00% | 18.69% | 25.57% | 24.19% | 17.99% | 15.53% | 14.19% | 13.40% | 13.77% | 14.82% | 12.30% | 11.85% | 10.62% | 11.72% | 10.38% | 11.71% | 10.00% | 6.38% | 10.01% | 10.77% | 8.81% | 7.45% | 1.56% | 8.69% | 10.06% | 9.72% | 11.44% | 9.69% | 11.20% | 11.34% | 9.89% | 7.20% | 4.75% | 5.03% | 3.07% | 3.84% | 1.96% | 3.71% | 1.84% |
| Total Other Income/Expenses | -561.00M | -558.00M | -1.19B | -567.00M | -524.00M | -521.00M | -531.00M | -434.10M | -399.60M | -415.80M | -290.10M | -212.70M | -112.40M | -100.30M | -121.80M | -79.80M | -93.10M | -32.59M | -7.88M | 4.78M | 35.25M | 131.50M | 42.32M | -23.90M | -230.10M | -28.30M | -100.30M | 17.40M | -8.30M | -7.20M | -13.60M | 19.80M | 33.70M | 15.40M | 16.40M | 8.20M | 15.20M | 4.90M | 6.90M |
| Income Before Tax | 6.30B | 7.84B | 8.84B | 7.23B | 4.07B | 3.26B | 2.43B | 2.02B | 1.94B | 2.09B | 1.32B | 1.27B | 1.13B | 1.16B | 927.10M | 1.15B | 881.30M | 209.37M | 285.90M | 259.22M | 218.63M | 287.99M | 76.52M | 174.26M | 18.50M | 347.50M | 414.00M | 301.60M | 239.00M | 172.60M | 110.00M | 88.10M | 72.00M | 51.00M | 34.20M | 27.40M | 22.70M | 17.20M | 11.80M |
| Income Before Tax Ratio | 14.70% | 17.44% | 22.55% | 22.43% | 15.93% | 13.39% | 11.61% | 11.08% | 11.41% | 12.36% | 10.08% | 10.15% | 9.61% | 10.79% | 9.17% | 10.95% | 9.04% | 5.52% | 10.86% | 11.75% | 10.43% | 13.80% | 3.50% | 7.64% | 0.75% | 8.98% | 11.63% | 10.28% | 10.83% | 10.89% | 8.80% | 9.28% | 8.94% | 7.20% | 5.91% | 5.47% | 5.92% | 5.19% | 4.44% |
| Income Tax Expense | 284.00M | 703.00M | 1.11B | 850.00M | 374.00M | 324.00M | 201.00M | -1.40M | -43.90M | 191.70M | 40.40M | 11.00M | 107.00M | 131.50M | 75.80M | 160.90M | 101.70M | 43.05M | 87.60M | 40.85M | 45.94M | 92.99M | 26.93M | 112.22M | 33.10M | 170.70M | 174.70M | 110.80M | 98.90M | 69.20M | 33.40M | 27.50M | 24.90M | 17.10M | 9.60M | 7.30M | 4.60M | 2.90M | 2.20M |
| Net Income | 6.00B | 6.95B | 7.73B | 6.38B | 3.70B | 2.94B | 2.23B | 2.02B | 1.98B | 1.89B | 1.27B | 1.18B | 1.33B | 1.04B | 850.30M | 994.20M | 761.10M | 168.94M | 223.22M | 361.84M | 200.01M | 309.73M | -781.00K | -36.11M | -174.60M | 181.90M | 239.30M | 190.80M | 140.10M | 103.40M | 76.60M | 59.20M | 47.10M | 33.90M | 24.60M | 20.10M | 18.10M | 14.30M | 9.60M |
| Net Income Ratio | 13.99% | 15.47% | 19.70% | 19.79% | 14.47% | 12.06% | 10.64% | 11.06% | 11.64% | 11.22% | 9.73% | 9.42% | 11.34% | 9.60% | 8.41% | 9.47% | 7.81% | 4.46% | 8.48% | 16.40% | 9.54% | 14.85% | -0.04% | -1.58% | -7.07% | 4.70% | 6.73% | 6.51% | 6.35% | 6.52% | 6.13% | 6.24% | 5.85% | 4.79% | 4.25% | 4.02% | 4.72% | 4.31% | 3.61% |
| EPS | 15.53 | 17.73 | 19.61 | 16.10 | 9.24 | 7.31 | 5.64 | 5.12 | 4.96 | 4.76 | 3.53 | 3.24 | 3.49 | 2.57 | 2.06 | 2.34 | 1.81 | 0.86 | 1.38 | 2.22 | 1.23 | 1.84 | 0.00 | -0.22 | -1.11 | 1.12 | 1.57 | 1.35 | 1.11 | 0.93 | 0.33 | 0.18 | 0.17 | 0.14 | 0.11 | 0.10 | 0.09 | 0.07 | 0.04 |
| EPS Diluted | 15.45 | 17.64 | 19.46 | 15.98 | 9.17 | 7.24 | 5.59 | 5.09 | 4.92 | 4.71 | 3.48 | 3.21 | 3.46 | 2.53 | 2.01 | 2.25 | 1.72 | 0.84 | 1.36 | 2.17 | 1.20 | 1.73 | 0.00 | -0.22 | -1.10 | 1.08 | 1.41 | 1.22 | 0.99 | 0.82 | 0.29 | 0.17 | 0.16 | 0.13 | 0.10 | 0.09 | 0.09 | 0.07 | 0.04 |
| Weighted Avg Shares Out | 386.00M | 392.00M | 394.00M | 396.00M | 400.00M | 402.00M | 395.00M | 394.80M | 398.70M | 398.20M | 360.30M | 363.80M | 380.80M | 403.30M | 412.40M | 418.20M | 421.50M | 196.10M | 161.59M | 163.13M | 162.71M | 168.33M | 181.59M | 164.14M | 157.99M | 162.41M | 152.48M | 141.53M | 125.48M | 110.80M | 107.71M | 91.04M | 87.06M | 70.60M | 61.06M | 58.72M | 57.91M | 58.74M | 48.80M |
| Weighted Avg Shares Out (Dil) | 388.00M | 394.00M | 397.00M | 399.00M | 403.00M | 406.00M | 398.00M | 397.40M | 401.90M | 402.30M | 365.80M | 366.60M | 384.80M | 409.40M | 423.03M | 434.70M | 443.70M | 203.70M | 165.33M | 167.64M | 170.73M | 179.03M | 185.02M | 164.14M | 158.22M | 168.43M | 169.79M | 175.70M | 158.10M | 145.53M | 107.71M | 91.04M | 87.06M | 70.60M | 61.06M | 58.72M | 57.91M | 58.74M | 48.80M |
Why Thermo Fisher (TMO) International Revenue Trends Deserve Your Attention
Explore how Thermo Fisher's (TMO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
The Zacks Analyst Blog Meta, Tesla, Thermo Fisher Scientific and Food Comes From
Meta, Tesla, Thermo Fisher Scientific and Food Comes From are included in this Analyst Blog.
Tradepulse Power Inflow Alert: Thermo Fisher Scientific Inc. Climbs Over 9 Points On Session After Alert
Thermo Fisher Scientific, Inc. today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.
Thermo Fisher Scientific Inc. (TMO) Q3 2024 Earnings Call Transcript
Thermo Fisher Scientific Inc. (NYSE:TMO ) Q3 2024 Earnings Conference Call October 23, 2024 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President and Chief Executive Officer Stephen Williamson - Senior Vice...
Thermo Fisher (TMO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Thermo Fisher (TMO) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Thermo Fisher Q3 Earnings Top Estimates, Revenues Miss, Stock Dips
In the third quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.
Thermo Fisher Scientific Q3: Expecting Market Recovery In FY25; Upgrade To 'Buy'
I am upgrading Thermo Fisher Scientific Inc. to a “Buy” with a fair value of $610 per share due to anticipated recovery in the pharma and biotech industries. Thermo Fisher's high-impact innovations and strategic M&A, including the acquisition of Olink,...
Thermo Fisher Scientific (TMO) Q3 Earnings Top Estimates
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.28 per share, beating the Zacks Consensus Estimate of $5.25 per share. This compares to earnings of $5.69 per share a year ago.
Thermo Fisher raises profit forecast on strong demand for its tools and services
Thermo Fisher Scientific on Wednesday raised the lower end of its annual profit forecast, tweaking it for the third time this year, betting on improved demand for its tools and services used in drug development.
Thermo Fisher Scientific Reports Third Quarter 2024 Results
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Highlights Third quarter revenue was $10.60 billion. Third quarter GAAP...
Source: https://incomestatements.info
Category: Stock Reports